ABBV · AbbVie Inc.

S&P 500 #24 · NYSE

Risiko 4/10 · Pharma Blue-Chip · $263.20 ▲ 2.45%

Kennzahlen

• Price $263.20
• Market cap $465.0B
• P/E (ttm) 129.66
• Div yield 2.69%
• 52-wk range $187.62 – $266.92
• Index rank #24 / —

Wichtigste Risiken

• Humira biosimilar revenue erosion (Revenue base) — HIGH
• Drug pricing legislation (IRA) (Margins) — MED
• Pipeline clinical trial risk (Future growth) — MED
• Stretched trailing PE post-run (Valuation) — MED

Fazit

AbbVie has rebounded strongly from its 2025 lows with Skyrizi and Rinvoq picking up Humira's slack, reaching a 52-week high; a sky-high trailing PE reflects one-time charges rather than steady earnings power.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.